ClinicalTrials.gg
RecruitingNCT07069569Updated Jul 29, 2026

A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs

A Phase 2 interventional study of AHB-137 and Peg-IFN in Chronic Hepatitis B, sponsored by Ausper Biopharma Co., Ltd.. Recruiting at 14 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Ausper Biopharma Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic — 6 open to participants now, 8 under way, 1 of them phase 3. Hepatitis B Virus Antisense Oligonucleotide AHB-137 · Hepatitis B, Chronic.

Planned enrollment
3rd of 11
200 · median 86
Started
2025
with 3 others
Phase 2
7 of 11
5 open now
Registered
5th of 11
by date
Lead sponsor
8 of 11
Ausper Biopharma Co., Ltd.

Among the 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic, this one is the 3rd largest by planned enrollment, is one of 4 that started in 2025, is one of 7 in phase 2, and was the 5th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

6 of the 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About Hepatitis B Virus Antisense Oligonucleotide AHB-137

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

This is a randomized, open-label, multicenter phase II study to evaluate the efficacy and safety of AHB-137 injection in combination with other hepatitis B drugs in participants with HBeAg-negative CHB treated with NAs.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

Keywords

  • Hepatitis B, Chronic
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants voluntarily participate in the study, and sign the Form (ICF) prior to screening, able to complete the study according to the protocol;
  • Aged between 18 and 65 years at the time of signing the ICF;
  • (BMI) within the range of 18-30 kg/ m2;
  • HBeAg negative at screening;
  • or HBV DNA positive for at least 6 months;
  • Continue antiviral therapy with a single nucleoside (t) ide analogue for more than 6 months prior to screening;
  • (ALT) ≤ 2 × (ULN);
  • Effective as required.

Exclusion criteria

Exclusion Criteria:

  • Participants who are not eligible for treatment with Peg-IFN/recombinant vaccine;
  • abnormalities other than a history of chronic HBV infection;
  • Concomitant clinically significant other liver diseases;
  • Any serious infection other than chronic hepatitis B infection requiring intravenous anti-infective therapy within 1 month prior to screening;
  • positive, (HIV) positive, syphilis positive;
  • Significant liver fibrosis or cirrhosis at screening, or a liver stiffness value (LSM) > 9.0 kPa;
  • Previous/current manifestations of hepatic decompensation;
  • Diagnosis or suspicion of hepatocellular carcinoma, or alpha-fetoprotein concentration (AFP) ≥ 20 ng/mL at screening;
  • Obviously abnormal laboratory test results;
  • History of vasculitis or presence of signs, symptoms, or laboratory tests of underlying vasculitis, and previous/current other diseases that may be related to vasculitic conditions;
  • corrected for heart rate (Fridericia method) abnormal;
  • History of extrahepatic disease possibly related to HBV immune status;
  • Participants with a history of within the past 5 years or who are being evaluated for a possible malignancy;
  • Serious mental illness or history of serious mental illness prior to screening;
  • Suspected history of allergy to any component of the study drug, or allergic constitution;
  • Major trauma or major surgery within 3 months prior to screening, or planned surgery during the study;
  • Those who are participating in another clinical trial, or have not undergone a protocol-specified prior to this study;
  • Current use or use of any medication within 3 months prior to screening, with the exception of short courses (≤ 2 weeks) or use of topical/inhaled ;Those who have used immunomodulators and cytotoxic drugs within 6 months prior to the first dose;Or a history of vaccination within 6 months prior to screening or a plan during the trial;
  • Participants requiring regular long-term administration of anticoagulants or antiplatelet drugs;
  • Thyroid dysfunction;
  • Patients with uncontrolled epilepsy and other progressive neurological disorders;
  • Received any antisense oligonucleotides (ASO) or small molecule interfering ribonucleic acid (siRNA) drug;
  • Any other circumstance or condition that, in the opinion of the investigator, the participants are inappropriate for participation in the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    AHB-137 (16 weeks) and Peg-IFN

    Drug: AHB-137 · Drug: Peg-IFN

  • Experimental
    AHB-137 (24 weeks) and Peg-IFN

    Drug: AHB-137 · Drug: Peg-IFN

  • Experimental
    AHB-137 and Hepatitis B vaccine

    Drug: AHB-137 · Drug: Hepatitis B Vaccine

  • Experimental
    AHB-137

    Drug: AHB-137

  • Experimental
    AHB-137 (24 weeks) and Peg-IFN(24 weeks)

    R3 group

    Drug: AHB-137 · Drug: Peg-IFN

Interventions

  • AHB-137 will be injected.

  • Peg-IFN will be administered .

  • DrugHepatitis B Vaccine

    Hepatitis B vaccine will be administered.

06

What researchers measure

Primary outcomes

  1. Proportion of participants with persistent HBsAg < limit of detection (LOD) and HBV DNA < lower limit of quantification (LLOQ) at the 24th week after all treatment for CHB was discontinued.

    Time frame: up to 72 weeks

Secondary outcomes

  1. Proportion of participants with persistent HBsAg < LOD and HBV DNA < LLOQ .

    Time frame: Up to 72 weeks

  2. Detection of the serum concentration of HBsAg, HBsAb, HBV DNA, HBV RNA, HBcrAg, HBeAb,and HBeAg.

    Time frame: Up to 72 weeks

  3. Proportion of participants who met discontinuation criteria for NAs treatment at the end of the treatment period.

    Time frame: Up to 48 weeks

  4. Relapse rate after discontinuation of NAs therapy.

    Time frame: Up to 72 weeks

  5. Change from baseline in alanine aminotransferase (ALT) values and time to normalization of values.

    Time frame: Up to 72 weeks

  6. Relapse time after discontinuation of NAs therapy.

    Time frame: Up to 72 weeks

  7. Plasma concentrations of AHB-137.

    Time frame: Up to 48 weeks

  8. Serum concentrations of Peg-IFN.

    Time frame: Up to 48 weeks.

  9. Safety: Number and percentage of participants with detectable anti-drug antibodies (ADA).

    Time frame: Up to 72 weeks

  10. Safety: Changes of the hepatitis B quality of life (HBQOL) instrument in participants compared with baseline.

    This scale has 31 items, including 7 dimensions: psychological status, expected anxiety, vitality, shame, infectivity, health vulnerability, and viral response. Each item is scored on a 5-point scale, with higher scores indicating a more severe impact of hepatitis B on quality of life.

    Time frame: Up to 72 weeks

  11. Safety: Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAE) and clinically significant examination results.

    Examination including laboratory examination, electrocardiogram (ECG) examination.

    Time frame: Up to 72 weeks

  12. Safety: Monitoring the score changes of Columbia Suicide Severity Scale (CSSRS) .

    The CSSRS is a categorical, interviewer-rated instrument that screens for suicidal ideation (five items, 0-1 each) and suicidal behavior (six items, 0-1 each); the highest positive item defines the risk level rather than a total score. For ideation items 3-5 an additional 0-5 intensity rating can be recorded. Across all items the minimum value is 0 (absent) and the maximum is 1 (present); a score of 1 on any item indicates a worse outcome and triggers escalating clinical safeguards, with any behavior item being tantamount to a suicidal event.

    Time frame: Up to 72 weeks.

  13. Safety: Changes of the score of EuroQol Five-Dimension Five-Level Scale (EQ-5D-5L) in participants compared with baseline.

    The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

    Time frame: Up to 72 weeks

  14. Safety: Monitoring the score changes of Self-Rating Depression Scale (SDS).

    The SDS is a 20-item, 4-point Likert self-report scale that yields a raw sum of 20-80 points, conventionally converted to a standard score of 25-100 by multiplying the raw total by 1.25. Higher standard scores denote worse outcomes: \<50 normal, 50-59 mild, 60-69 moderate, and ≥70 severe depression, with ≥70 warranting specialist evaluation and suicide-risk assessment.

    Time frame: Up to 72 weeks.

  15. Discontinue all treatment for CHB for 24 weeks with HBV DNA<LLOQ and HBsAg<10IU/mL.

    Time frame: Up to 72 weeks

07

Study locations

14 of 14 sites recruiting
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing Municipality, China
    Recruiting
  • AusperBio Investigational Site
    Chongqing, Chongqing Municipality, China
    Recruiting
  • AusperBio Investigational Site
    Fuzhou, Fujian, China
    Recruiting
  • AusperBio Investigational Site
    Guangzhou, Guangdong, China
    Recruiting
  • AusperBio Investigational Site
    Guangzhou, Guangdong, China
    Recruiting
  • AusperBio Investigational Site
    Shenzhen, Guangdong, China
    Recruiting
  • AusperBio Investigational Site
    Shenzhen, Guangdong, China
    Recruiting
  • AusperBio Investigational Site
    Zunyi, Guizhou, China
    Recruiting
  • AusperBio Investigational Site
    Wuhan, Hubei, China
    Recruiting
  • AusperBio Investigational Site
    Changchun, Jilin, China
    Recruiting
  • AusperBio Investigational Site
    Chengdu, Sichuan, China
    Recruiting
  • AusperBio Investigational Site
    Chengdu, Sichuan, China
    Recruiting
  • AusperBio Investigational Site
    Kunming, Yunnan, China
    Recruiting
  • AusperBio Investigational Site
    Hangzhou, Zhejiang, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jul 2027, 25 months after the start.

Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's planned 25 months is above that.

Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2025
First posted
Jul 16, 2025
StartActual
Jun 8, 2025
Primary completionEst.
Jul 15, 2027
CompletionEst.
Jan 15, 2028
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07069569
Responsible party
Sponsor
First posted
Jul 16, 2025
Start date
Jun 8, 2025
Primary completion
Jul 15, 2027 (estimated)
Completion
Jan 15, 2028 (estimated)
Last update
Jul 29, 2026

Study contacts

Lu
Contact
clinicaltrial@ausperbio.com
0571-86959519
Jia
principal investigator · Beijing Friendship Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hepatitis B Virus Antisense Oligonucleotide AHB-137

Start the discussion